Artificial Intelligence (AI) has taken the lead in technological advancement across the pharmaceutical sector. It is expected to transform pre-clinical drug discovery through reducing costs by up to 40% and creating a market worth up to $50 billion in the next decade.
Are you ready for this transformative period?Hear first-hand the latest AI advancements across the pharmaceutical sector directly from experts in the field and obtain strategies to support your operations at the highly anticipated
AI in Drug Discovery conference. Driven by a move towards personalised therapies and novel drug candidates, Artificial Intelligence (AI) has taken the lead in technological advancement across the pharmaceutical sector. Increased efficiency of the drug discovery process, through innovations including automation, in-silico modelling, and machine learning, accelerate growth in an ever-expanding field, focused on revolutionising modern healthcare.
Why should you attend?
Get ready for the highly-anticipated return of the
AI in Drug Discovery Conference this March 2024. In the interim since our last gathering in March 2023, the industry has achieved a ground breaking milestone – the first wholly AI-discovered and designed drug is now undergoing Phase 2 clinical trials.
Four compelling reasons as to why you can't miss out:
- Gain insights from leading biotechs and big pharma on drug target selection
- Explore neural networks with a focus on digital twins, new drug designs and in-silico modelling to expand your portfolio
- Get the latest insights on the benefits of machine learning from molecule design to clinical trial selection, along with crucial patient-centric considerations.
- Discuss best use and potential impact of Generative AI in light of the launch of Chat GPT
Join us as we navigate through the hype and unveil effective strategies to harness the AI revolution for achieving tangible and transformative outcomes in the realm of drug design and discovery.
Benefit from the insights of our diverse speakers, leveraging their expertise to propel the field forward into clinical trials and introduce transformative new drugs to the market.
Who should attend?
Anyone that is interested in AI in Drug Discovery is welcome to join us as we face the latest market advancements. This event gives you the opportunity to drive the field forwards, from clinical trial design to drug target selection, allowing for a cheaper, more successful research and development process, in the pursuit to improve disease outcomes globally.
Featured Speakers
- Daniel Cohen, President, Valence Labs and Vice President, Recursion Pharmaceuticals
- Dr Anders Hogner, Associate Director, Medicinal Chemistry, AstraZeneca
- Dr Anne Goupil-Lamy, Science Council Fellow and Principal Field Application Scientist, BIOVIA
- Dr Carl Poelking, Senior Researcher, Computational Chemistry & Informatics, Astex Pharmaceuticals
- Dr Christina Schindler, Associate Director, Head of Computational Drug Design, Merck KGaA
- Dr Christophe Chabbert, Senior Scientist, Discovery Informatics,, Roche Pharma Research and Early Development (pRED)
- Dr Darren Green, Head of Cheminformatics & Data Science, Senior Felllow, GSK
- Dr Francois-Xavier Baludin de Thé, Computational Scientist, Servier Pharmaceuticals
- Dr Gerhard Hessler, Head of Synthetic Molecular Design, Sanofi
- Dr Grégori Gerebtzoff, Director, Pharmacokinetic Sciences (PKS), Biomedical Research, Novartis
- Dr Guglielmo Iozzia, Associate Director - Data Science, ML/AI, Computer Vision, MSD Ireland
- Dr Haruna Iwaoka, Senior Director, Advanced Modeling & Display, Discovery Intelligence, Astellas Pharma Inc.
- Dr Iain Moal, Scientific Leader, GSK Fellow, Computational Antibody Engineering, Medical Science & Technology, GSK Research & Development
- Dr James Lumley, Associate Director, Cheminformatics and Data Science, GSK
- Dr Maria Wendt, Global Head of Digital and and Biologics Strategy & innovation, Large Molecule Research, Sanofi
- Dr Martin Akerman, Co-Founder & CTO, Envisagenics
- Dr Martin-Immanuel Bittner, Co-Founder and CEO, Arctoris
- Dr Nadine Schneider, Lead, Generative Chemistry, Biomedical Research, Novartis
- Dr Nicola Richmond, VP of AI, BenevolentAI
- Dr Petrina Kamya, President of Insilico Medicine Canada and Vice President, Head of AI Platforms, Insilico Medicine
- Dr Rabia Khan, Founder & CEO, Serna.bio
- Dr Simone Fulle, Head of Protein Engineering, Novo Nordisk A/S
- Dr Thierry Dorval, Head of Data Sciences & Data Management, Servier Pharmaceuticals
- Dr Yogesh Sabnis, Director, Lead Design, UCB Biopharma srl
- Karl Leswing, Executive Director, Machine Learning, Schrödinger
- Martin Buttenschoen, Research Student, Oxford Protein informatics Group, University of Oxford
- Michael Edmund Beck, Distinguished Science Fellow, Bayer AG
- Philipe Moingeon, Professor, AI and Drug Sciences, Paris-Saclay University and Head of Immuno-Inflammation Portfolio, Servier Pharmaceuticals
- Philipp Lorenz, CTO, Basecamp Research
- Quentin Perron, Co-Founder & CSO, Iktos
Please fill in your name and email to receive the Conference Agenda of this event.
Venue
Hilton London Kensington
179-199 Holland Park Ave, Kensington, W11 4UL
London, UK
